---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-290820"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2023-12-08T23:59:59+00:00"
generated_at: "2026-06-07T15:27:36.057108+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# EyePoint prices $200M public offering at $17/share to fund Phase 3 trials for EYP-1901

## Summary
- Underwritten public offering of 11,764,706 shares priced at $17.00 per share; underwriters exercised option for additional 1,764,705 shares.
- Expected net proceeds ~$215.9M after underwriting discounts and expenses.
- Proceeds to fund two pivotal Phase 3 trials of EYP-1901 for wet AMD and other pipeline initiatives.
- Closing expected December 8, 2023; J.P. Morgan, TD Cowen, Guggenheim lead underwriters.
- Offering upsized from initial $175M to ~$200M gross.

## SEC filing metadata
- accession: 0001193125-23-290820
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2023-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312523290820/0001193125-23-290820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312523290820/d627747d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-290820
- JSON: https://secwatch.observer/filing/0001193125-23-290820.json
- Plain text: https://secwatch.observer/filing/0001193125-23-290820.txt

## Key facts
- Material Agreements
  EyePoint, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, as representative of the underwriters named therein valued at approximately $215.9 million (effective 2023-12-05).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC, as representative of the underwriters named therein
  - Value: approximately $215.9 million
  - Effective: 2023-12-05
  source text: On December 5, 2023, EyePoint Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, as representative of the underwriters named therein (the “Underwriters”), in connection with its previously announced underwritten public offering (the “Offering”) of 11,764,706 shares of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000119312523290820/0001193125-23-290820-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.